Emilio Bajetta

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study
    P Bidoli
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori i, Milan, Italy
    Ann Oncol 18:461-7. 2007
  2. pmc Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
    Emilio Bajetta
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer Manag Res 1:89-97. 2009
  3. ncbi Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer
    E Bajetta
    Medical Oncology Unit B, Unit of Experimental Oncology C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 14:242-7. 2003
  4. ncbi Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
    Emilio Bajetta
    S C Oncologia Medica 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian, 1, Milan 20133, Italy
    Cancer Chemother Pharmacol 59:637-42. 2007
  5. ncbi Capecitabine chemoradiation for rectal cancer after curative surgery
    E Bajetta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    J Chemother 18:85-9. 2006
  6. ncbi Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma
    E Bajetta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 17:571-7. 2006
  7. ncbi Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
    E Bajetta
    Medical Oncology Unit 2, ITMO Group, Nuclear Medicine, Department of Statistics, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
    Ann Oncol 16:1374-80. 2005
  8. ncbi Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
    Emilio Bajetta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milano, Italy
    J Clin Oncol 23:2155-61. 2005
  9. ncbi Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy
    Emilio Bajetta
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 90:449-57. 2004
  10. ncbi Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients
    Emilio Bajetta
    Department of Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Oncology 66:132-7. 2004

Detail Information

Publications133 found, 100 shown here

  1. ncbi Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study
    P Bidoli
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori i, Milan, Italy
    Ann Oncol 18:461-7. 2007
    ..Many patients with advanced non-small-cell lung cancer (NSCLC) do not tolerate cisplatin-based regimens because of its nonhemathological toxicity...
  2. pmc Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
    Emilio Bajetta
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer Manag Res 1:89-97. 2009
    ..The present review will discuss the role of palonosetron in the prevention of acute CINV...
  3. ncbi Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer
    E Bajetta
    Medical Oncology Unit B, Unit of Experimental Oncology C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 14:242-7. 2003
    ....
  4. ncbi Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
    Emilio Bajetta
    S C Oncologia Medica 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian, 1, Milan 20133, Italy
    Cancer Chemother Pharmacol 59:637-42. 2007
    ..The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours' (NETs) treatment...
  5. ncbi Capecitabine chemoradiation for rectal cancer after curative surgery
    E Bajetta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    J Chemother 18:85-9. 2006
    ..Capecitabine chemoradiation in the adjuvant setting is well tolerated and is convenient to administer. These results support the use and further study of capecitabine chemoradiation in radically resected rectal cancer patients...
  6. ncbi Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma
    E Bajetta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 17:571-7. 2006
    ..In this phase III trial, we compared the effects of CT [cisplatin, vindesine and dacarbazine (CVD)] with those of concurrent biochemotherapy (bioCT) consisting of CVD plus interleukin-2 and interferon-alpha2b...
  7. ncbi Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
    E Bajetta
    Medical Oncology Unit 2, ITMO Group, Nuclear Medicine, Department of Statistics, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
    Ann Oncol 16:1374-80. 2005
    ..The aim of this trial was to apply the new classification criteria in clinical practice and, accordingly, to choose the most appropriate treatment...
  8. ncbi Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
    Emilio Bajetta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milano, Italy
    J Clin Oncol 23:2155-61. 2005
    ..To evaluate the safety and efficacy of capecitabine in older women with advanced breast cancer...
  9. ncbi Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy
    Emilio Bajetta
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 90:449-57. 2004
    ..Epoetin alfa treatment in patients with a variety of malignancies has been shown to decrease transfusion requirements and improve hemoglobin levels and quality-of-life efficacy parameters...
  10. ncbi Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients
    Emilio Bajetta
    Department of Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Oncology 66:132-7. 2004
    ..The aim of this study was to evaluate the activity and tolerability of irinotecan followed by oxaliplatin in patients with FU-resistant colorectal cancer...
  11. ncbi Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma
    Emilio Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Cancer 100:279-87. 2004
    ..The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)...
  12. ncbi Update on the treatment of neuroendocrine tumors
    Emilio Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Expert Rev Anticancer Ther 3:631-42. 2003
    ..Novel therapies, new pharmacological formulations and more selective somatostatin analogs are now under clinical investigation for the treatment of neuroendocrine tumors...
  13. ncbi Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer
    E Bajetta
    Medical Oncology Unit B and Department of Radiology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 14:1543-8. 2003
    ..The aim of this study was to assess the activity of pemetrexed in patients with advanced gastric cancer...
  14. pmc Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study
    E Bajetta
    Department of Medical Oncology, Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori of Milano, Milano, Italy
    Br J Cancer 96:439-44. 2007
    ..The safety profile of the two combinations also allows an evaluation with other biological agents such as monoclonal antibodies...
  15. ncbi Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study
    Emilio Bajetta
    Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer 107:2474-81. 2006
    ....
  16. doi Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma
    Giuseppe Procopio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
    Oncology 73:204-9. 2007
    ..The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice...
  17. doi Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients
    Emilio Bajetta
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer Chemother Pharmacol 64:67-72. 2009
    ..This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients...
  18. ncbi Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes
    Emilio Bajetta
    Unit of Medical Oncology2, Centro di Riferimento per lo Studio e la Cura dei Carcinoidi e dei Tumori Neuroendocrini Ce Ri Ca Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 95:501-7. 2009
    ..Therefore, increased rates of false neuroendocrine tumors represent an emerging problem in clinical practice. Our aim is to alert clinicians on this matter by supplying them with useful warnings...
  19. ncbi Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma
    Emilio Bajetta
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milan 20133, Italy
    Nat Clin Pract Oncol 5:4-5. 2008
  20. ncbi Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer
    E Bajetta
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 18:1810-6. 2007
    ....
  21. ncbi Renal cell cancer and sorafenib: skin toxicity and treatment outcome
    Emilio Bajetta
    Unit of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 93:201-3. 2007
    ..The hypothesis of the correlation of skin toxicity with disease response is not new, but in the absence of any strong evidence remains controversial...
  22. ncbi Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer
    Diego Cortinovis
    Medical Oncology Unit B, National Cancer Institute, Milan, Italy
    Tumori 90:186-91. 2004
    ....
  23. ncbi Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial
    Maria Di Bartolomeo
    Medical Oncology Unit 2, Fondazione IRCCS, Istituto Nazionale dei Tumori of Milano, Milano, Italia
    Oncology 71:341-6. 2006
    ..In this paper, we present the results of a phase III trial in which these two combinations given sequentially were compared to mitomycin C (MMC) monochemotherapy in an adjuvant setting...
  24. ncbi Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer
    Paolo Bidoli
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milano 20133, Italy
    Lung Cancer 43:203-8. 2004
    ..The primary endpoint of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of OHP/GEM combination in non-small cell carcinoma of the lung...
  25. ncbi Treatment of cancer-related anemia with epoetin alfa: a review
    Erminia Ferrario
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Treat Rev 30:563-75. 2004
    ..Determining the timing of initiation of epoetin alfa is a clinical judgement; however, data suggest that patient functioning declines and the risk of transfusion increases when the Hb level falls under 12 g/dL...
  26. ncbi Medical treatment and other combination regimens
    Emilio Bajetta
    Unità di Oncologia Medica 2, Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    Tumori 93:suppl 22-6. 2007
  27. ncbi Pulmonary carcinoid tumours: indolent but not benign
    Sara De Dosso
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
    Oncology 73:162-8. 2007
    ..The aim of this retrospective study was to analyse the malignant behaviour of low-grade pulmonary neuroendocrine tumours (NETs) treated at our institution...
  28. doi Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?
    Laura Catena
    Oncologia Medica 2, Fondazione IRCCS Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, Italy
    Tumori 97:564-7. 2011
    ....
  29. ncbi An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review
    Nicoletta Zilembo
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 96:1031-4. 2010
    ..She showed an impressive response to this first-line chemotherapy and, after disease progression, to further chemotherapy with gemcitabine and vinorelbine. She is still alive, with unexpectedly long-lasting survival...
  30. ncbi Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition
    Elena Beretta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 92:379-83. 2006
    ..In the present study we report the safety and efficacy results combining CPT-11 with 5-fluorouracil (5-FU) and folinic acid (FA)...
  31. doi Oxaliplatin doublets in non-small cell lung cancer: a literature review
    Diego Cortinovis
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Lung Cancer 60:325-31. 2008
    ..We performed a literature search in order to better understand the possible role of oxaliplatin-based combinations in advanced NSCLC treatment strategies...
  32. doi Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
    Diego Cortinovis
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Thorac Oncol 3:405-11. 2008
    ..In this setting, docetaxel (D) has shown efficacy and irinotecan (I) has only recently been introduced. This study was initiated to explore the activity and tolerability of three D + I regimens in platinum pretreated NSCLC patients...
  33. ncbi Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
    Leonardo Ferrari
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, I 20133 Milano, Italy
    Int J Oncol 22:1081-9. 2003
    ..The observed variations seem to be mainly linked to the circulating oestrogen levels rather than directly to the way of action of the AI employed...
  34. ncbi Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate
    Antonia Martinetti
    Nuclear Medicine Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Anticancer Res 23:3485-91. 2003
    ....
  35. pmc Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase I
    Luigi Celio
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy
    Support Care Cancer 21:565-73. 2013
    ....
  36. ncbi A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma
    Emilio Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 94:299-304. 2002
    ....
  37. ncbi Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer
    Emilio Bajetta
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 95:43-7. 2009
    ..Since there is no internationally adopted standard regimen, we have conducted a pilot study of COI in untreated advanced gastric cancer...
  38. ncbi The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients
    Nicoletta Zilembo
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Biomed Pharmacother 58:255-9. 2004
    ..This approach can be used in clinical practice in order to offer a disease control with a satisfactory quality of life...
  39. ncbi Renal cancer treatment: a review of the literature
    Luca Gattinoni
    Operative Unit of Medical Oncology B, National Cancer Institute, Milan, Italy
    Tumori 89:476-84. 2003
    ..New approaches such as monoclonal antibodies, vaccines, gene therapy, angiogenesis inhibitors and allogeneic cell transplantation and their possible clinical applications are also discussed...
  40. ncbi Treatment options in hormone-refractory metastatic prostate carcinoma
    Alberto Fusi
    Medical Oncology Unit B, National Institute for the Study and the Treatment of Tumors, Milan, Italy
    Tumori 90:535-46. 2004
    ..The evaluation and incorporation of new agents into current treatment regimens could have a role in the treatment of hormone-refractory prostate cancer, but their efficacy has not yet been demonstrated...
  41. ncbi Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC)
    Daniela De Candis
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Am J Clin Oncol 26:265-9. 2003
    ....
  42. ncbi Merkel cell carcinoma after liver transplantation: a case report
    Emilio Bajetta
    Unit of Medical Oncology 2, Centro di Riferimento per lo Studio e la Cura del Carcinoide e dei Tumori Neuroendocrini CeRiCa, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 93:323-6. 2007
    ..Merkel cell carcinoma is a rare and aggressive neuroendocrine skin cancer with a very low incidence in the general population. MCC seems to be common in transplant recipients and 52 cases have been reported in the literature...
  43. ncbi Metastatic melanoma: chemotherapy
    Emilio Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Semin Oncol 29:427-45. 2002
    ..New chemotherapeutic and biologic agents are now available and promising combined approaches targeting the tumor by several different mechanisms are desirable and will probably represent the future modality of treatment...
  44. pmc Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
    Luigi Celio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy
    Support Care Cancer 19:1217-25. 2011
    ....
  45. doi Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial
    Luigi Celio
    Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Support Oncol 10:65-71. 2012
    ..The non-inferiority of palonosetron plus 1-day versus 3-day dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) due to moderately emetogenic chemotherapy (MEC) has been previously demonstrated...
  46. doi Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer
    Vera Cappelletti
    Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
    Endocr Relat Cancer 15:439-49. 2008
    ..Integration between neo-adjuvant therapy and transcriptional profiling has therefore the potential to identify therapeutic targets to be challenged for overcoming treatment resistance...
  47. ncbi Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy
    Silvia Della Torre
    Medical Oncology Unit B, National Cancer Institute, Milan, Italy
    Tumori 89:111-6. 2003
    ..On these bases, it is recommended that diagnosis and treatment of neuroendocrine tumors be carried out at specialized oncological centers involved in clinical trials...
  48. ncbi Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients
    Vera Cappelletti
    Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Endocr Relat Cancer 11:761-70. 2004
    ....
  49. ncbi Pemetrexed in gastric cancer: clinical experience and future perspectives
    Luigi Celio
    Medical Oncology Unit B and Department of Radiology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Semin Oncol 29:63-8. 2002
    ..This article discusses how pemetrexed may be investigated in future clinical trials in gastric cancer...
  50. ncbi Neuroendocrine tumors of the larynx: a clinical report and literature review
    Giuseppe Procopio
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 92:72-5. 2006
    ..Because of the very low incidence of neuroendocrine tumors in the larynx, a review of the literature has also been performed...
  51. ncbi Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report
    Filippo Pietrantonio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Tumori 96:154-6. 2010
    ..Clinicians should be aware of this adverse event in order to prevent possible serious consequences and stop further oxaliplatin administration...
  52. ncbi Impressive objective response in a patient with extensive metastatic melanoma including the brain
    Michele Del Vecchio
    Department of Medical Oncology and Radiology, Istituto Nazionale Tumori, Milan, Italy
    Melanoma Res 17:332-4. 2007
  53. ncbi Prostate adenocarcinoma presenting with supraclavicular node enlargement: report of a case
    Marco Platania
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Tumori 94:769-71. 2008
    ..We emphasize the importance of PSA immunohistochemistry and serum PSA level monitoring in men presenting with carcinoma of undetermined origin and generalized lymphadenopathies...
  54. doi Single-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone
    Emilio Bajetta
    Department of Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Via G Venezian 1, Milan, Italy
    Ann Surg Oncol 16:2985-93. 2009
    ..To determine the long-term outcomes of early-stage Merkel cell carcinoma (MCC) patients managed with surgery alone...
  55. doi A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer
    Sara Pusceddu
    Medical Oncology Unit 2, Department of Pathology, Anatomic Pathology A Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Crit Rev Oncol Hematol 81:185-95. 2012
    ..Diagnostic approaches and therapeutic procedures on primary MM of the uterine cervix are discussed following a review of the literature encompassing more than one century...
  56. doi Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors
    Michele Del Vecchio
    Unit of Medical Oncology 2, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 16:5862-72. 2010
    ..To assess the clinical and biological activity of the association of bevacizumab and fotemustine as first-line treatment in advanced melanoma patients...
  57. ncbi Integrated therapeutic strategies for anaplastic thyroid carcinoma
    Roberto Buzzoni
    UO Oncologia Medica B, National Cancer Institute, Milan, Italy
    Tumori 89:544-6. 2003
    ..Different therapeutic options have been explored but the results are disappointing. At present, new drugs and new timing for proper treatment are under investigation. In this short review we have summarized these recent developments...
  58. doi Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration
    Giuseppe Procopio
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, Milan, Italy
    BJU Int 108:223-7. 2011
    ..To assess the efficacy of ketoconazole in patients with castration-resistant prostate cancer (CRPC)...
  59. doi Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer
    Maria Di Bartolomeo
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Drugs Aging 28:83-91. 2011
    ..Careful selection of patients and monitoring of treatment effects are required to optimize use of the antiangiogenic agent bevacizumab in older patients...
  60. ncbi Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting
    Luigi Celio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 94:447-52. 2008
    ..However, palonosetron may offer advantages of convenience over the short-acting older antagonists due to its ability to be given as a single intravenous dose prior to chemotherapy...
  61. ncbi Interleukin-12: biological properties and clinical application
    Michele Del Vecchio
    Medical Oncology Unit 2, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy
    Clin Cancer Res 13:4677-85. 2007
    ..More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients...
  62. ncbi Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer
    A Cassata
    Medical Oncology Unit B, National Cancer Institute, Milan, Italy
    Tumori 87:364-71. 2001
    ..Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-containing regimes for advanced colorectal and breast cancer...
  63. pmc Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:5569-75. 2008
    ..To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer...
  64. doi Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report
    Sara Pusceddu
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Int J Gynecol Pathol 27:596-600. 2008
    ..Despite its rarity, this variant of MM should be considered when a diagnosis of cervix MPNST is made. The histological and immunohistochemical features of these different entities should be considered in the differential diagnosis...
  65. ncbi Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma
    E Bajetta
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 84:48-51. 1998
    ..Therefore, there is no indication to employ this regimen as second-line treatment in metastatic melanoma and these disappointing results highlight the urgent need for new therapeutic approaches...
  66. ncbi FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer
    D L Cortinovis
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Curr Cancer Drug Targets 8:342-8. 2008
    ..This retrospective study indicates that FHIT-/p53+ status might be a biological variable influencing the efficacy of carboplatin/gemcitabine treatment in NSCLC...
  67. ncbi Formestane: effective therapy in postmenopausal women with advanced breast cancer
    E Bajetta
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 5:S15-7. 1994
    ..We conclude that formestane is an effective aromatase inhibitor in postmenopausal patients with hormone-dependent breast cancer, and does not interfere with adrenal steroidogenesis...
  68. ncbi Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole
    A Martinetti
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Endocr Relat Cancer 11:771-9. 2004
    ..OPG and OPN appear to be useful predictors of the outcome of skeletal disease and elevated OPN values may be associated with short survival in advanced breast cancer patients...
  69. ncbi Formestane: an effective first-line endocrine treatment for advanced breast cancer
    N Zilembo
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Cancer Res Clin Oncol 121:378-82. 1995
    ..Local and systemic tolerability was satisfactory. We conclude that formestane is an effective and well-tolerated agent in previously untreated patients, and that these results should be confirmed by further studies...
  70. ncbi Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus
    Paolo Bidoli
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 94:352-61. 2002
    ..The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma...
  71. ncbi Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma
    Michele Del Vecchio
    Department of Medical Oncology, Istituto Nazionale dei Tumori of Milan, Italy
    J Clin Oncol 22:745-6. 2004
  72. ncbi Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients
    L Ferrari
    Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori of Milan, Via G Venezian, 1, 20133 Milan, Italy
    J Steroid Biochem Mol Biol 80:411-8. 2002
    ....
  73. ncbi Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary
    F Nole
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 79:116-8. 1993
    ..The results of treatment strategies for carcinoma of an unknown primary location have been discouraging. Currently, no chemotherapeutic approach can be considered standard...
  74. pmc Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
    S Siena
    Ospedale Niguarda Ca Granda, Milan, Italy
    Br J Cancer 97:1469-74. 2007
    ..Overall survival favoured no PD patients vs PD patients alive at week 8. Lack of disease progression was associated with better symptom control, HRQoL, and OS...
  75. ncbi Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study
    M Di Bartolomeo
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 85:211-3. 1999
    ..Combined preoperative therapy with oral fluoropyrimidine plus l-leucovorin together with radiation may be an attractive approach in patients with operable rectal cancer...
  76. ncbi Clinical significance of blood chromogranin A measurement in neuroendocrine tumours
    E Seregni
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 12:S69-72. 2001
    ..CgA evaluation is recommended in the follow-up of patients with such tumours...
  77. ncbi Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors
    N Zilembo
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Acta Oncol 32:245-50. 1993
    ..The radiometabolic therapy appears promising in symptomatic patients with small tumor burden whereas our chemotherapy regimen appears ineffective...
  78. ncbi Combined carboplatin and cytosine arabinoside in metastatic melanoma refractory to dacarbazine
    E Bajetta
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 81:238-40. 1995
    ..Moreover, the regimen is well tolerated and easy to administer in an outpatient setting...
  79. pmc Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor
    N Zilembo
    Division of Medical Oncology B, Istituto Nazional per lo Studio e la Cura dei Tumori, Milan, Italy
    Br J Cancer 72:1007-12. 1995
    ..The overall objective response rate was 18%. In conclusion, exemestane is effective in reducing oestrogen levels at all of the tested doses and shows interesting clinical activity...
  80. ncbi Ovarian ablation for premenopausal early-stage breast cancer: an update
    L Celio
    Medical Oncology B Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 86:191-4. 2000
    ..Here we review current evidence supporting the value of this ablative procedure as an adjuvant and update ongoing clinical research to refine our knowledge about its use...
  81. ncbi Pharmacokinetics of oral doxifluridine in patients with colorectal cancer
    M G Zampino
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 85:47-50. 1999
    ..CONCLUSIONS: A large interpatient pharmacokinetic variability was observed without any significant correlation with the clinical parameters studied...
  82. doi Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study
    L Celio
    Medical Oncology Unit 2, Foundation IRCCS National Tumour Institute, Milan, Italy
    Ann Oncol 20:1062-7. 2009
    ..This clinical trial assessed the efficacy of pemetrexed combined with oxaliplatin (PEMOX) in patients with advanced gastric cancer (AGC)...
  83. doi Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases
    Alessandro Zerbi
    Pancreatic Surgery Section, Humanitas Scientific Institute, Via Manzoni 56, Rozzano, Milan, Italy
    Langenbecks Arch Surg 396:313-21. 2011
    ..Information on the treatment of pancreatic endocrine tumours (PETs) comes mostly from small, retrospective, uncontrolled studies...
  84. ncbi Doxifluridine: an active agent in advanced gastrointestinal cancer
    M Di Bartolomeo
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 81:147-50. 1995
    ..CONCLUSIONS: Our results indicate that doxifluridine may be superior to fluorouracil, the biochemical modulator as folinic acid seems to enhance its activity in colorectal patients. The oral schedule is feasible for home treatment...
  85. ncbi Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid
    M Colleoni
    Division of Medical Oncology B, Istituto Nazionale Tumori, Milan, Italy
    Tumori 78:258-61. 1992
    ..FA should be associated with fluoropyrimidine as first-line therapy together with other biochemical modulators. Further rescue therapies need to be developed...
  86. ncbi Adjuvant chemotherapy for cancer of gastrointestinal tract: a critical review
    F de Braud
    Divisione di Oncologia Medica, Istituto Nazionale Tumori, Milano, Italy
    Tumori 78:228-34. 1992
    ..The role of adjuvant therapy for gastric cancer is debated. The recent development of regimens active on advanced disease result in more promising future adjuvant trials...
  87. ncbi Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results
    E Seregni
    Nuclear Medicine, National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 54:84-91. 2010
    ..Aim of this study was to evaluate the feasibility, the efficacy and the toxicity of this treatment in neuroendocrine tumors expressing somatostatin receptors relapsed or refractory to conventional therapies...
  88. ncbi Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours
    E Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori di Milano, Italy
    Ann Oncol 13:614-21. 2002
    ..The present study aimed to assess in a multidisciplinary manner the efficacy of the same regimen at intensified doses in patients with advanced NETs...
  89. ncbi Quality of life assessment and clinical decision-making
    P Casali
    Division of Medical Oncology A, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 8:1207-11. 1997
    ..Providing average quality of life scores may be useful, indeed, for population-based health decisions, as are those on resource allocation and those on registration of new drugs...
  90. ncbi Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer?
    E Bajetta
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 82:417-22. 1996
    ..Challenges given by these novel aromatase inhibitors are discussed taking into account the biologic implications related to their mechanism of action and their future use in the management of breast cancer...
  91. ncbi Fluoropyrimidines in the treatment of advanced neoplastic diseases: role and advantages of UFT
    M del Vecchio
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 85:6-11. 1999
    ..Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally...
  92. ncbi Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors
    E Bombardieri
    Nuclear Medicine Division, Istituto Nazionale Tumori, Milan, Italy
    Q J Nucl Med Mol Imaging 48:150-63. 2004
    ..allows the interpretation of radiopharmaceutical uptake as a prognostic parameter and sometimes as a predictor of the response to treatment...
  93. ncbi Aromatase inhibitors in the treatment of postmenopausal breast cancer
    E Bajetta
    Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Drugs Aging 15:271-83. 1999
    ..However, we feel that concomitant biological and clinical studies should also be carried out in order to clarify the properties of these drugs and avoid possible risks for patients over time...
  94. ncbi Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors
    E Bajetta
    Division of Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 11:1017-22. 2000
    ..In an attempt to investigate the relationship between tumor response and estrogen suppression, we reviewed the hormonal and clinical data of two previous studies with formestane (250 and 500 mg i.m. fortnightly) in advanced BC patients...
  95. ncbi A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma
    E Bajetta
    Unit of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 87:219-22. 2001
    ....
  96. ncbi [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?]
    E Bombardieri
    Unità Operativa Medicina Nucleare, Istituto Nazionale Tumori Milano, Milan, Italy
    Minerva Endocrinol 26:197-213. 2001
    ..Aim of this review is to summarize the potential of nuclear medicine techniques in the diagnosis of neuroendocrine tumours and to stresses the renewed role of nuclear medicine in the management of this disease...
  97. ncbi Advances in diagnosis and therapy of neuroendocrine tumors
    E Bajetta
    Operative Unit of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 1:371-81. 2001
    ..Chemotherapy is the best choice in the treatment of neuroendocrine tumors characterized by a poor differentiation grade and a high proliferation rate...
  98. ncbi Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism
    E Bajetta
    Medical Oncology Unit B and Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 13:1059-66. 2002
    ..To study the short-term biological effect of anastrozole on serum estrogens, androgens, 17-hydroxyprogesterone (17OH-PGR), gonadotrophins, sex hormone binding globulin (SHBG) and bone metabolism markers...
  99. ncbi Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group
    E Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori of Milano, Milan, Italy
    Ann Oncol 13:299-307. 2002
    ....
  100. pmc FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study
    E Bajetta
    ITMO, c o Division of Medical Oncology B of Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Br J Cancer 77:1149-54. 1998
    ..The patients randomized to receive low-dose GM-CSF achieved a significantly higher dose intensity than controls (P = 0.0001)...